Significance of 18F-Fluorodeoxyglucose (FDG) Uptake in Response to Chemoradiotherapy for Pancreatic Cancer
暂无分享,去创建一个
S. Natsugoe | Y. Mataki | T. Arigami | K. Maemura | H. Shinchi | H. Kurahara | S. Ueno | Masahiko Sakoda | Y. Kijima | S. Mori | Satoshi Iino | Y. Kawasaki | Yuko Mataki
[1] T. Arisawa,et al. Use of count-based image reconstruction to evaluate the variability and repeatability of measured standardised uptake values , 2018, PloS one.
[2] S. Natsugoe,et al. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma , 2018, Annals of surgical oncology.
[3] F. Motoi,et al. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma , 2018, Journal of Gastrointestinal Surgery.
[4] E. Nakakura,et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, The Journal of the National Comprehensive Cancer Network.
[5] M. Partridge,et al. Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).
[6] T. Strom,et al. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy , 2017, Acta oncologica.
[7] S. Shiraishi,et al. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer , 2017, Annals of Surgical Oncology.
[8] Yonghong Shi,et al. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients , 2017, Oncotarget.
[9] C. Lyssiotis,et al. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. , 2017, Cancer cell.
[10] M. Yano,et al. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence , 2016, Annals of surgery.
[11] M. Büchler,et al. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer , 2016, The British journal of surgery.
[12] T. Murakami,et al. The correlation between FDG uptake and biological molecular markers in pancreatic cancer patients. , 2016, European journal of radiology.
[13] M. Malafa,et al. Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma , 2016, Pancreas.
[14] David Goldstein,et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.
[15] R. Korn,et al. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas† , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Shuihong Zhou,et al. Co-Inhibition of GLUT-1 Expression and the PI3K/Akt Signaling Pathway to Enhance the Radiosensitivity of Laryngeal Carcinoma Xenografts In Vivo , 2015, PloS one.
[17] J. Long,et al. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. , 2015, Cancer letters.
[18] Xianjun Yu,et al. Role of SUVmax obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation , 2013, Nuclear medicine communications.
[19] J. Bussink,et al. Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy , 2012, Clinical Cancer Research.
[20] S. Natsugoe,et al. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer , 2012, Journal of hepato-biliary-pancreatic sciences.
[21] H. Eguchi,et al. Perineural Invasion and Lymph Node Involvement as Indicators of Surgical Outcome and Pattern of Recurrence in the Setting of Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Pancreatic Cancer , 2012, Annals of surgery.
[22] D. Bentrem,et al. Apigenin down-regulates the hypoxia response genes: HIF-1α, GLUT-1, and VEGF in human pancreatic cancer cells. , 2011, The Journal of surgical research.
[23] Jeffrey E. Lee,et al. Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here? , 2011, Annals of Surgical Oncology.
[24] A. Levine,et al. The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.
[25] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[26] S. Natsugoe,et al. Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer. , 2008, Anticancer research.
[27] J. Berlin,et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Hoskin,et al. Positron emission tomography in oncology: a review. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).
[29] Eric J. W. Visser,et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[30] S. Jinnouchi,et al. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. , 2006, Journal of hepato-biliary-pancreatic surgery.
[31] E. Paulson,et al. Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer , 2005, Annals of Surgical Oncology.
[32] J. Best,et al. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.
[33] T. Saga,et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[35] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[36] H. Minn,et al. F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, Multidetector Row Computed Tomography, and Magnetic Resonance Imaging in Primary Diagnosis and Staging of Pancreatic Cancer , 2009 .